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ABSTRACT
Aims: BRCA1 gene mutations have been extensively
studied in relation to breast and ovarian cancer
susceptibility. Various genotype–phenotype correlation
attempts have yielded important data pertaining to the
consequences of BRCA1 mutations. However, little is
known about the effects of recurrent BRCA mutations on
expressivity and the age of onset of cancer in a
population. This study addresses whether different exon
mutations have variable expressivity especially in relation
to the age of onset of breast cancer.
Methods: Using a step-wise systematic approach,
culminating in the sequencing of all BRCA1 and BRCA2
exons with the addition of multiplex ligation-dependent
probe amplification, the relationship between disease
phenotypes and gene mutations in 219 individuals and
their family members was examined.
Results: It is shown that different BRCA1 gene mutations
have distinct effects that influence the age of onset of
breast or ovarian cancer. Mutations in exon 2 of the
BRCA1 gene had significantly lower penetrance compared
with mutations of exons 11, 13 and 20. The median age
of affliction with breast cancer was 55 years for
185delAG in exon 2 (95% confidence interval (CI) 46.7 to
59.5), 47 years for the 4184delTCAA mutation in exon 11
(95% CI 39 to 55.4), and 41 years for exon 13 duplication
(95% CI 32.9 to 49.7) of the BRCA1 gene. Moreover, 14
novel mutations in BRCA1 and BRCA2 genes in the
Yorkshire/Humberside population were identified.
Conclusions: The 185delAG mutation of the BRCA1 gene
is a low penetrance mutation that is age dependent
especially when compared with the exon 13 duplication
mutation. The data have important ramifications on
screening, genetic counselling and prophylactic treatment
of BRCA1 gene mutation carriers.
Breast cancer is the most prevalent malignancy in
women.
1 In the western hemisphere the lifetime
risk of developing breast cancer is more than 10%.
Ovarian cancer, on the other hand accounts for a
lifetime risk of 1.8%.
2 The majority of breast and
ovarian cancers are sporadic or not inherited.
Germline mutations in the breast and ovarian
cancer susceptibility genes BRCA1 (MIM 113705)
3
and BRCA2 (MIM 600185)
45confer a high risk of
developing breast and ovarian cancers. Women
with a mutation in the BRCA1 gene have a lifetime
risk of 80–90% of developing breast cancer, and 40–
65% chance of developing ovarian cancer.
6 For
BRCA2 gene mutation carriers, the estimated
cumulative risk of breast cancer has been shown
to be 28% by age 50 years, and 84% by age
70 years.
7 The risk of ovarian cancer has been
shown to be 0.4% by age 50 years and 27% by age
70 years.
7 Nevertheless, the magnitude of risk to
carriers of the germline BRCA1 and BRCA2 remains
controversial
2 and the controversy could partly
have stemmed from the use of different popula-
tions and study designs, and the lack of specific
mutation stratification.
8
The Breast Cancer Information Core Database
(BIC) lists more than 1560 and 1880 mutations and
polymorphisms in the BRCA1 and BRCA2 genes
respectively. The influences of each mutation type
(genotype) on expressivity, cancer type and age-
dependent penetrance (phenotype) remain either
controversial or unexplored. In the last decade,
several reports have been published supporting the
hypothesis that different mutations in the BRCA1
or BRCA2 genes confer different cancer-related
risks. For example, Gayther et al (1995) reported
that the risk of ovarian cancer relative to the risk of
breast cancer was higher in families with muta-
tions located 59 to exon 13 of the BRCA1 gene
compared with families with mutations located 39
to exon 13.
9 However, this finding was not
confirmed in later reports.
10–12 Also, an ovarian
cancer cluster region (OCCR) in the BRCA2 gene
was described by Gayther et al (1997).
13 A later
international collaborative study provided no
statistically significant support for the existence
of such a region,
14 rather it was suggested that a
reduced absolute risk of breast cancer for OCCR
mutations contributed substantially to the effect
described.
15 All the above data pooled different but
neighbouring BRCA1 or BRCA2 mutations and
associated them with phenotypes. However, does a
specific mutation in the BRCA1 or BRCA2 gene
confer different phenotypes compared with other
common mutations in the same gene? This is a
question that remains unanswered especially per-
taining to the recurrent BRCA1 exon 2, 11 and 13
mutations. The answer to this question could have
important implications for screening, genetic
counselling and prophylactic treatment of carriers.
Therefore, there is currently a need to study the
genotype–phenotype correlation among common
mutations in BRCA1 and BRCA2 genes. Our paper
addresses this need.
METHODS
Patients
A total of 241 patients and their family members
from Yorkshire and Humberside, UK, were chosen
for BRCA1 and BRCA2 mutation testing. They
belonged to 131 families classified as moderate to
high risk of carrying a BRCA1 or BRCA2 mutation.
High-risk individuals were members of families
with four confirmed cases of breast and/or ovarian
cancers, with breast cancer occurring under the
age of 60 years or ovarian cancer at any age.
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of cancer. Patients were followed up for a mean of
81.87 months (range 0.33–343.6 months), and age at diagnosis
and overall survival were recorded. Mutational and correspond-
ing clinical data were available for 219 cases. For calculating age
at diagnosis, the age and date at which cancer of the breast or
ovary occurred was noted. For calculating overall survival, the
date of death was recorded. In addition, for other subjects with
a follow-up date, but no date of death, this was coded as
censored. For one subject with no follow-up time recorded but
dates of diagnosis and follow-up, the follow-up time was
calculated from the dates.
All patients and family members were counselled and signed a
written informed consent before testing. The procedures
followed were in accordance with the ethical standards
implemented at the University of Kuwait and with the
Declaration of Helsinki 1975, as revised in 1983.
Mutation testing
High-quality DNA was extracted from 5 ml EDTA-treated
venous blood samples using a standard phenol–chloroform
procedure. All DNA samples were screened for mutations at
exon 2 (185delAG), exon 20 (5382insC) of BRCA1, and exon 11
(6147delT) of BRCA2, using amplification refractory mutation
system PCR and duplication (Exon13dup6kb) of exon 13 by
multiplex ligation-dependent probe amplification (P002; MRC-
Holland, Amsterdam, The Netherlands) as instructed by the kit
manufacturer (level 1 testing). DNA negative for these muta-
tions was subjected to level 2 testing, which involved direct
sequencing of all exon 11 in eight large PCR fragments. Negative
samples were then subjected to level 3 testing that called for
single-strand conformation polymorphism (SSCP) analysis and
sequencing of all BRCA1 coding exons. Therefore, all samples
that were negative for levels 1, 2 and SSCP were sequenced. In
all reactions, positive (DNA with known mutations) and
negative controls (wild-type DNA from normal individuals)
were included. Primer sequences and reaction conditions are
available online.
16
Statistical analysis
Two outcomes were considered: age at diagnosis and time from
diagnosis to death. As both of these are time to event data, Cox
proportional hazards regression was used. Four groups of
subjects were compared, defined by the exon where the
mutation took place: exon 2, exon 11, exon 13 and all other
exons. The hazard ratio for each group, exon 2, 11 and 13,
compared to the other exons group were calculated, with an
overall significance test of the effect of exon and confidence
intervals for each hazard ratio. Patients were grouped into
pedigrees, where more than one patient may belong to the same
pedigree. Clustering within pedigrees was be adjusted for using
robust standard errors by the method of Lin and Wei.
17 For the
time to death, we also controlled for age at diagnosis, to allow
for potentially greater mortality among older women. All
analyses were done using Stata 8 (Stata, College Station,
Texas, USA).
RESULTS
BRCA1 and BRCA2 mutation frequencies in Yorkshire
The present study included 131 families with moderate to high
risk of carrying BRCA1 or BRCA2 mutations (table 1). An
example pedigree from a family with exon 13 duplication is
shown in supplementary fig 1. A total of 241 patients and their
family members were screened for pathogenic germline muta-
tions in the BRCA1 or BRCA2 gene.
One hundred and thirty-six (56%) individuals carried a
mutated BRCA1 gene, 25 (10%) had a mutated BRCA2 gene,
and 80 (33%) of the screened individuals carried wild-type
genes. Tables 2 and 3 give the frequency and type of mutations
in various exons of BRCA1 and BRCA2 genes respectively. The
vast majority of mutations caused protein truncation.
Moreover, we identified 14 novel mutations not previously
reported in the BIC database.
18
For the BRCA1 gene, mutations in exon 11 were the most
frequent (n=58, or 42.3%) with 4184delTCAA accounting for
the most common mutation within exon 11 (n=29, or 50%).
Exon 2 mutations were the second most frequent (n=30, or
22%) with 185delAG being the most common mutation within
exon 2 (n=28, or 93.3%) followed by mutation of exon 13
(n=20, or 14.6%) and exon 20 (n=12, or 8.7%). For BRCA2
Table 1 Breakdown of families with the most frequent BRCA1
mutations
Family Mutation
Gene/
exon
No of
individuals
No of
mutation
carriers
No
affected
761 185delAG BRCA1/2 41 0
2802 185delAG BRCA1/2 26 11 3
5358 185delAG BRCA1/2 21 1
9603 185delAG BRCA1/2 11 0
9877 185delAG BRCA1/2 44 1
12654 185delAG BRCA1/2 11 1
13376 185delAG BRCA1/2 21 1
17240 185delAG BRCA1/2 22 2
17924 185delAG BRCA1/2 21 1
21347 185delAG BRCA1/2 22 2
27388 185delAG BRCA1/2 42 1
30231 185delAG BRCA1/2 21 1
2592 4184delTCAA BRCA1/11 32 1
7836 4184delTCAA BRCA1/11 43 1
9117 4184delTCAA BRCA1/11 42 1
9430 4184delTCAA BRCA1/11 32 2
10079 4184delTCAA BRCA1/11 32 1
10502 4184delTCAA BRCA1/11 21 1
11096 4184delTCAA BRCA1/11 31 1
12779 4184delTCAA BRCA1/11 31 1
14028 4184delTCAA BRCA1/11 22 2
14562 4184delTCAA BRCA1/11 32 1
16324 4184delTCAA BRCA1/11 11 1
29694 4184delTCAA BRCA1/11 74 3
32778 4184delTCAA BRCA1/11 11 1
33164 4184delTCAA BRCA1/11 11 1
39265 4184delTCAA BRCA1/11 33 3
40426 4184delTCAA BRCA1/11 11 0
3140 Exon13 Dup BRCA1/13 32 1
3429 Exon13 Dup BRCA1/13 22 1
9592 Exon13 Dup BRCA1/13 31 1
12157 Exon13 Dup BRCA1/13 1 1 Unknown
12468 Exon13 Dup BRCA1/13 22 1
20332 Exon13 Dup BRCA1/13 21 1
20597 Exon13 Dup BRCA1/13 11 1
21231 Exon13 Dup BRCA1/13 21 1
25940 Exon13 Dup BRCA1/13 22 1
27810 Exon13 Dup BRCA1/13 21 1
32563 Exon13 Dup BRCA1/13 22 2
36387 Exon13 Dup BRCA1/13 11 1
38199 Exon13 Dup BRCA1/13 21 1
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75%).
Association of BRCA1 and BRCA2 gene mutations with cancer
occurrence and site
Matched mutations and clinical data were available for 219
individuals. The cohort included 40 (18%) males and 179 (82%)
females. As expected, there was a significant association
between the presence of BRCA1 or BRCA2 mutations and the
occurrence of cancer; p,0.0001 (table 4). Of the affected cases,
63 had invasive breast cancer, 12 were diagnosed with ovarian
cancer, 15 had both breast and ovarian cancers, one man
Table 2. Frequencies and types of BRCA1 familial mutations
Exon no
Familial
mutation
No of individuals (%) with
BRCA1 mutations (n=136)
11 917_918delTT 1 (1.7)
887insAG* 1 (1.7)
887insA* 1 (1.7)
4184delTCAA 29 (49.2){
3896delT 5 (8.5)
3889delAG 3 (5.1)
3875delGTCT 2 (3.4)
3519G.T (E1134X) 1 (1.7)
3450_3453delCAAG 1 (1.7)
2871A.C* 1 (1.7)
2800delAA 1 (1.7)
2682C.T (Q855X) 1 (1.7)
2594delC 2 (3.4)
2559insA* 1 (1.7)
2196G.A (D693N) 1 (1.7)
2080delA 1 (1.7)
2011insT 1 (1.7)
1927C.G* 1 (1.7)
1623del5bp 2 (3.4)
1294del40bp 2 (3.4)
Total 58
13 Ex13ins6kb 4 (20)
ex13 dup 14 (70)1
4446C.T (R1443X) 2 (10)
Total 20
15 4693delAA 1 (50)
4654G.T (S1512I) 1 (50)
Total 2
16 5075G.A (M1652I) 1 (100)
Total 1
1A–2 Exons 1A–2 deletion 2 (100)
Total 2
2 187–188delAG* 1 (3.3)
185insA{ 1 (3.3)
185delAG 28 (93.3)"
Total 30
20 ivs20+60 ins12bp 1 (8.3)
Exon 20 deletion 7 (58.3)
5382insC 4 (33.3)
Total 12
22 5452–2A.C* 1 (100)
Total 1
24 5622C.T (R1835X) 5 (100)
Total 5
3 Exon 3 deletion 3 (100)
Total 3
5 300T.C (C61R) 1 (100)
Total 1
7 421–2delA 1 (100)
Total 1
*Novel mutations not reported in the Breast Cancer Information Core database.
{Reported in Pakistan.
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{Number of families=13.
1Number of families=12.
"Number of families=11.
Table 3. Frequencies and types of BRCA2 familial mutations
Exon no
Familial
mutation
No of individuals (%) with
BRCA2* mutations (n=25)
11 6714_6717delACAA 2 (11.8)
6503delTT 1 (5.9)
6174delT 1 (5.9)
6137C.A (S1970X) 2 (11.8)
5950delCT 2 (11.8)
5368delATTT* 1 (5.9)
5056insG* 3 (17.6)
4859insA 2 (11.8)
4329insA* 1 (5.9)
4329delA* 1 (5.9)
3386T.G (L1053X) 1 (5.9)
3036delACAA 1 (5.9)
Total 18
2 295G.T 4 (100)
Total 4
23 9138insA* 1
Total 1
8 860–1G.A* 2 (100)
Total 2
*Novel mutations not reported in Breast Cancer Information Core database.
Figure 1 (A) Cumulative incidence for all cancer cases, by various
BRCA1 exons. (B) Cumulative incidence of breast cancer cases, by
various BRCA1 exons.
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with ovarian and vaginal cancers, and another woman
presented with breast and pancreatic adenocarcinomas. Table 5
lists cancer sites in relation to BRCA1 and BRCA2 mutations.
Mutations in the BRCA1 gene accounted for the majority of
breast and ovarian cancers in these families. In addition, BRCA1
mutations accounted for the majority of patients with both
breast and ovarian cancers. BRCA2 mutations were more
common in breast than ovarian cancer (the ratio of breast to
ovarian cancers was 9:1). This is consistent with data from the
Breast Cancer Linkage Consortium.
7 Although the numbers
were modest, mutations in the BRCA2 gene were significantly
associated with the development of cancers outside the breast–
ovarian axis (table 5).
There was evidence that mutations in the 39 end of the
BRCA1 gene (39 to exon 13) were less likely to be associated
with ovarian cancer. For example, 90% of ovarian cancers were
associated with mutations in the 59 end of the BRCA1 gene,
while only 10% were linked to mutations in the 39 end.
However, this trend was not statistically significant.
BRCA1 exon 2 mutation penetrance
We noted that carriers of the exon 2 BRCA1 gene mutation had
significantly lower cancer incidence compared with carriers of
mutations of exons 11, 13 and 20. In this regard, table 6 shows
that 15 (56%) of patients who carried the BRCA1 185delAG
mutation were cancer free (p=0.004). This suggested to us that
either the 185delAG mutation is of low penetrance or, more
likely, carriers of this mutation would develop cancer at an older
age compared with other BRCA1 gene mutations. This
observation led us to explore age-dependant expressivity of
various BRCA1 exon mutations.
BRCA1 mutations and age-related expressivity
Of the 136 cases carrying a mutated BRCA1 gene, 79 women
who developed breast and/or ovarian cancers were included in
the analysis (table 7). Analysis of age-related expressivity
pertaining to various BRCA2 gene mutations was not performed
because of the small number of cases included in each mutation
category. For BRCA1 gene, groups of patients were compared,
defined by the exon where the mutations were located: exon 2,
exon 11, exon 13, and all other exons. Patients were grouped
into pedigrees, where more than one patient may belong to the
same pedigree. Cox regression with clustering on pedigree
showed that the exon was a highly significant predictor (x
2
19.75 with 3 degrees of freedom, p=0.0002). Hence, there was
a significant relationship between a specific exon mutation and
age at diagnosis, mainly due to exon 2 having a much lower
hazard or older age at diagnosis than the other groups (table 7).
Clustering within pedigrees may have an adverse effect on
pvalues and standard errors. The cumulative incidence for all
cancer cases, or limited to breast cancers, and stratified by
various BRCA1 exon mutations is shown in fig 1.
We then asked if the relationship between various BRCA1
exon mutations and age at diagnosis is different for different
cancer sites. For this, we carried out Cox regression analysis
with exon and tumour site as factors. The estimates of the
hazard ratios were very little changed by including both exon
and tumour site (x
2 statistic 23.09 with 5 degrees of freedom,
p=0.0003) (table 8). Also, limiting the analysis to woman with
breast cancer only, the hazard ratios changed very little (table 9).
This is not surprising, as most of the women belonged to this
group. Hence there is strong evidence that various BRCA1 exon
mutations have an effect on age-dependent expressivity that
was not explained by cancer site.
Specific BRCA1 mutations and age-related expressivity
Exon 11 is the largest exon in the BRCA1 gene and harbours a
number of different mutations in different patients; these
mutations were grouped in this study under the term ‘‘exon 11
mutations’’. To minimise any confounding error emanating
from such grouping, we limited the analysis to three specific and
most common mutations in exons 2, 11 and 13, namely,
185delAG, 4184delTCAA and exon 13 duplication, respectively
(table 1). Figure 2 shows that median age of affliction with
breast cancer was 55 years for 185delAG in exon 2 (hazard ratio
(HR) 0.23, 95% CI 0.095 to 0.55, p=0.001) and 47 years for the
4184delTCAA mutation in exon 11 (HR 0.49, 95% CI 0.225 to
1.08, p=0.076) compared with 41 years for exon 13 duplication
of the BRCA1 gene. It is worthy of note that the inclusion of a
large pedigree (2802) carrying the 185delAG mutation could
have confounding influence on the major conclusion emanating
from our study. However, exclusion of this pedigree from the
analysis did not have any impact on our data stating that exon 2
Table 4 Clinical characteristics of patients in relation to BRCA1 and
BRCA2 mutations
Clinical data
Number
of
patients
or age
Mutations in
BRCA1 and
BRCA2
genes
Wild-type
BRCA1 and
BRCA2
genes
p
Value*
Phenotype
No with cancer 102 98 4 0.0001
No cancer free 117 44 73
Mean age (years) 47.7
Mean age of patients with
cancer
46 45.8 49.2 0.006{
Mean age of cancer-free
individuals
49.2 46.7 50.8
*Calculated using two-sided Fisher’s exact test.
{Student t test was used to compare means.
Table 5 Cancer sites in relation to BRCA1 and BRCA2 mutations
Cancer site*
Mutation
in
BRCA1
Mutation in
BRCA2 Total p Value{
Breast 54 9 63 0.001
Ovary 12 0 12
Breast and ovary 13 2 15
Breast or ovary and other
sites
02 2
Other sites 0 1 1
Total 79 14 93
*Site was unknown for five of 98 patients with cancer (three with exon 11, and two
other exon mutations in the BRCA1 gene).
{Calculated using two-sided Fisher’s exact test.
Table 6 Relationship between various mutated BRCA1 exons and
affliction with cancer
Mutated exon no.
Affected with cancer,
n=84 (%)
Cancer free,
n=37 (%) Total, n=121
11 38 (71.7) 15 (28.3) 53
13 13 (72.2) 5 (27.8) 18
2 12 (44.4) 15 (55.6)* 27
Other exons 21 (91) 2 (9) 23
*p=0.004 using two-sided Fisher’s exact test.
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(HR 0.22, 95% CI 0.09 to 0.56, p=0.002).
BRCA1 mutations and survival analysis
Overall survival data were available from 61 patients. The Cox
regression with clustering on pedigree, including BRCA1 exon
mutation and age at diagnosis, gave no overall significant
prediction: x
2=3.72 with 4 degrees of freedom, p=0.4. Thus
there was no evidence that any specific BRCA1 exon mutation
can predict overall survival from date of diagnosis. However, as
expected, risk of death increased slightly with age at diagnosis,
though this was not significant. The raised HRs suggest that
this analysis would be worth repeating with a much larger
sample (fig 3).
DISCUSSION
The aim of this study was to elaborate on the expressivity of
various BRCA1 gene mutations in relation to penetrance and age
of cancer diagnosis. To this end, a total of 241 patients and their
family members (of whom 219 had relevant clinical data) were
screened for pathogenic germline mutations in BRCA1 or BRCA2
genes and the results were associated with clinical parameters.
We opted for a family-based study to maximise the number of
individuals with mutated BRCA1 or BRCA2 genes. Although
this approach suffers from bias compared with a population-
based study, it was necessary as the latter approach requires a
very large cohort to attain a similar number of individuals with
mutated BRCA1 or BRCA2 genes. Therefore, .4000 individuals
in a population are required to be tested to yield 141 individuals
with BRCA1 or BRCA2 mutations.
19 The extent of bias is
difficult to infer. For example, it is generally accepted that
family-based studies usually overestimate the lifetime risks of
cancer because the presence of additional genetic factors could
elevate risks for the relatives. Nevertheless, the use of appro-
priate statistical methods could alleviate some aspects of this
bias.
20 21
In this study we have exhaustively searched for mutations in
the BRCA1 and BRCA2 genes using a level approach that
involved starting from screening for known founder mutations
up to sequencing all exons in addition to various exon
rearrangements. This methodology would increase the sensitiv-
ity of detecting BRCA1 and BRCA2 gene mutations, and this
was reflected in our high pickup mutation rate accounting for
67% of individuals recruited in this study. A total of 56% of
individuals harboured a BRCA1 mutated gene; this figure is
similar to the one previously estimated for the UK population.
9
Similarly, the proportion of BRCA2 mutation-bearing indivi-
duals in this study is within the range previously published for
the UK.
22 It is well accepted that mutation frequencies of the
BRCA1 and BRCA2 genes in high-risk families vary widely
among different populations, being highest in Russia for
BRCA1
23 and in Iceland for BRCA2.
24 This could be due to
ascertainment or methodological bias, or more likely it is a
reflection of human migration and establishment of founders.
In our UK East Midlands series, three mutations in the BRCA1
gene were recurrent, namely 4184delTCAA, accounting for the
most common mutation within exon 11 (found in 16 families),
185delAG, being the most frequent mutation within exon 2
(found in 11 families), and duplication of exon 13 (found in 12
families). The BIC database lists 185delAG, 4184delTCAA and
exon 13 duplication among the 20 most frequent recurrent
mutations
18; these are consistent with our data. Also, our data
are in line with the fact that BRCA1 exon 13 duplication has
been reported as a founder mutation in Britain, and English-
speaking counties with historical links to Britain. In that regard,
50% of the exon 13 duplication mutations were demonstrated
in Britain, mainly Yorkshire, suggesting a northern British origin
for this mutation (the BRCA1 exon 13 screening group).
25
Interestingly, none of the BRCA2 mutations were repeated in
more than two families, probably indicating the presence of
many BRCA2 founders (or de novo mutations). Although we
did not haplotype families carrying the 185delAG mutation,
previous haplotypes from Yorkshire indicated independent
origins of the mutation from the Jewish founders.
26
Our data are consistent with the fact that mutations in
BRCA1 and BRCA2 are associated with increased risk of
cancer.
32 7Both BRCA1 and BRCA2 mutations were significantly
associated with development of breast cancer. On the other
hand, BRCA2, but not the BRCA1 gene, was significantly linked
to the development of cancer outside the breast–ovarian axis.
This is in agreement with data showing that mutations in the
BRCA1 gene are rarely linked to cancer at sites other than breast
and ovary, while mutations in the BRCA2 gene are.
28 29
Regarding the controversial issue linking mutations of the 39
end of the BRCA1 to lower incidence of ovarian cancer, our data
show that ovarian cancer is indeed lower when mutations
inflict the 39 end of the BRCA1 gene. However, the trend was
insignificant and a larger study is needed to resolve this issue.
9
Perhaps the most intriguing finding of this study was the
notion that different mutations in the BRCA1 gene have
significantly different effect on age-dependent expressivity. To
the best of our knowledge this is the first time that different
age-dependent expressivity, independent of cancer site, has been
reported for three of the most common BRCA1 mutations,
namely 185delAG, 4184delTCAA and exon 13 duplication. For
the exon 13 duplication mutation, we reported a mean age of
cancer diagnosis at 41.4 years (95% CI 36.99 to 45.78) from 12
independent families. Data on the age-dependent penetrance/
expressivity for exon 13 duplication are scarce. However, Unger
Table 7 Cox regression analysis between specific BRCA1 exon
mutation and age at diagnosis
Mutation Hazard ratio Standard error p Value (95% CI)
Exon 11 0.69 0.21 0.2 (0.38 to 1.25)
Exon 2 0.28 0.09 ,0.001 (0.15 to 0.54)
Exon 13 1.16 0.51 0.7 (0.49 to 2.75)
Hazard ratio of ,1 indicates lower hazard than the other groups and hence older ages
at diagnosis.
Table 8 Cox regression analysis including specific BRCA1 exon
mutation and cancer sites as covariates
Mutation Hazard ratio p Value (95% CI)
Exon 11 0.64 0.1 (0.37 to 1.11)
Exon 2 0.29 ,0.001 (0.15 to 0.53)
Exon 13 0.98 0.97 (0.40 to 2.42)
Ovary 0.46 0.009 (0.26 to 0.82)
Other exons 0.76 0.3 (0.47 to 1.24)
Table 9 Cox regression analysis between specific BRCA1 exon
mutation and age at diagnosis limited to breast cancer only
Mutation Hazard ratio p Value (95% CI)
Exon 11 0.61 0.1 (0.32 to 1.13)
Exon 2 0.26 0.002 (0.11 to 0.62)
Exon 13 0.80 0.6 (0.32 to 2.03)
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developed cancer at age 34 years.
30 Moreover, Yap et al reported
a woman diagnosed with bilateral breast cancer at ages 32 and
41 years and her sister, carrying the same exon 13 duplication
mutation, was diagnosed with ovarian cancer at age 43 years.
31
For the 185delAG BRCA1 mutation, although the frequency of
the mutation was, as expected, among the highest, we report
significantly lower cancer rates in carriers of this mutation. This
has been observed before in Iraqi/Iranian women, who have a
significantly lower penetrance compared with Ashkenazi Jewish
woman carrying the same mutation.
32 Therefore, it remains to
be elucidated whether this difference in penetrance could be due
to other genetic variation such as different haplotypes,
environmental or cultural influences. More importantly, we
report here that the mean age of cancer diagnosis from 12
separate families carrying the 185delAG mutation was 55 years
(95% CI 49.3 to 60.7), which is a significantly older age of cancer
diagnosis compared with exon 13 duplication mutation. In a
recent report, using a meta-analysis of pedigree data from 498
BRCA1 and BRCA2 mutation carriers identified through
population-based studies of women with breast and ovarian
cancer, the authors have shown, albeit not significantly, that
cancer risk by age 50 years is lower for 185delAG than 5382insC
BRCA1 mutation carriers.
19 33 Our data are consistent with this.
The question of why the 185delAG mutation has a lower
cancer-related expressivity that is age dependent compared to
other BRCA1 mutations remains to be elucidated. Recently,
however, Perrin-Vidoz et al, reported that transcripts bearing
the 185delAG mutation are not subjected to degradation by
nonsense-mediated mRNA decay.
34 This important observation
leads us to hypothesise that even in the presence of the
185delAG mutation there could still be some truncated, but
functional, BRCA1 protein delaying the onset of cancer. In
support of this, Buisson et al have demonstrated translational
re-initiation in the BRCA1 minigenes at position 128 in the
presence of a premature termination codon at position 36 or
39.
35 However, using western blotting and immunoprecipita-
tion, we and Buisson et al were unable to detect N-terminally or
Figure 2 Kaplan–Meier plots of cumulative survival and age at diagnosis with breast cancer in relation to specific BRCA1 exon mutations. The p value
indicates log-rank test.
Figure 3 Kaplan–Meier plot of overall survival of patients in relation to
BRCA1 exon mutations (the table depicts the hazard ratios).
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J Clin Pathol 2009;62:350–356. doi:10.1136/jcp.2008.062646 355C-terminally truncated BRCA1 proteins from lymphocytes of
carriers, probably indicating an unstable nature of the truncated
BRCA1 protein.
35 Nevertheless, the truncated BRCA1 protein
could still be functional in a microenvironment or at concentra-
tions beyond the detection limit of current technologies. This
hypothesis remains to be proven. Obviously, the role of other
genetic background or haplotypes and environmental influences
on age-dependent expressivity cannot be underestimated. For
example, we do not know whether carriers of exon 13
duplication in the BRCA1 gene have other genetic aberrations
that could influence expressivity. Regardless of the mechanism,
our findings have important ramifications regarding the design
of future studies for the estimation of cancer risks and more
specifically on the counselling of patients with BRCA1 muta-
tions, in that the mutation type should be included in risk
calculations. Moreover, the time of screening and prophylactic
treatments of carriers should be adjusted to take into account
the different age-dependent expressivity of various BRCA1 gene
mutations.
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